COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL
COMPARISON OF CABERGOLINE VERSUS RALOXIFENE ADD-ON THERAPY TO LONG-ACTING SOMATOSTATIN ANALOGUE IN PATIENTS WITH INADEQUATELY CONTROLLED ACROMEGALY: A RANDOMIZED OPEN LABEL CLINICAL TRIAL
复制标题
DOI：
10.4158/ep-2017-0195
复制
发表时间：
2018-06-01
影响因子：
4.2
通讯作者：
Malek, Mojtaba
中科院分区：
文献类型：
--
作者：
Imani, Mehrnaz;Khamseh, Mohammad Ebrahim;Malek, Mojtaba
目的：本研究的目的是评估卡麦角林与雷洛昔芬的长效生长抑素类似物（SAs）控制不佳的肢端肥大症患者的疗效的添加治疗。方法：这是一个前瞻性的，随机的开放标签的临床试验。44例患者（每组22例）完成了研究;参与者以平行方式接受卡麦角林（3 mg/周）或雷洛昔芬（60 mg，每日两次）添加治疗12周。主要结局是血清胰岛素样生长因子1（IGF-1）较基线的降低率。次要结果包括血清IGF-1随年龄和性别的正常化。结果：卡麦角林组和卡麦角林组的血清IGF-1均显着降低（40.3 +/-25.6%，P
Objective: The present study aimed to evaluate the efficacy of add-on therapy of cabergoline versus raloxifene to long-acting somatostatin analogues (SAs) in patients with inadequately controlled acromegaly.Methods: This was a prospective, randomized open label clinical trial. Forty-four patients (22 per group) completed the study; where participants received either cabergoline (3 mg/week) or raloxifene (60 mg twice daily) add-on therapy for 12 weeks in a parallel manner. The primary outcome was the rate of reduction in serum insulin-like growth factor 1 (IGF-1) from baseline. Secondary outcomes comprised normalization of serum IGF-1 for age and sex.Results: Serum IGF-1 was significantly decreased in both the cabergoline (40.3 +/- 25.6%, P